12 didactic best practices to develop the most efficient Learning Virtual Environment

In this paper, We build the best Learning Virtual Environment pedagogic structure for keep inside the best methodology and resources areas for students, teachers, canal, relationship… and whatever element into an educational community. For this, we draw twelve didactic best practices to be followed for an efficient elearning system

Del estudio de las prácticas inclusivas y de enseñanza creativa en un colegio rural agrupado al inicio de un proceso de investigación en la acción

Las prácticas inclusivas y creativas de enseñanza se presentan como un aspecto fundamental para atender a la heterogeneidad existente en las aulas. La investigación-acción constituye una gran oportunidad para alcanzar los objetivos planteados en el estudio: identificar prácticas de enseñanza creativa en la escuela rural, conocer las representaciones de las mismas y ver cuáles son los cambios que los docentes incorporan a sus prácticas tras el proceso. Observación participante, entrevista y conversaciones informales han formado parte de un proceso de investigación en la acción en un Colegio Rural Agrupado de la Comunidad Autónoma de Aragón (España). Los resultados muestran el desarrollo de prácticas de enseñanza creativa en el Colegio Rural Agrupado a pesar de que el profesorado no sea consciente de ello, atendiendo así a las necesidades del alumnado, al mismo tiempo que los docentes entran en un proceso de revisión, reflexión y cuestionamiento de las mismas. Estos resultados podrían de interés para las políticas educativas relacionadas tanto con la escuela rural como la urbana, así como para todos aquellos agentes implicados en el estudio

Final results regarding the addition of dendritic cell vaccines to neoadjuvant chemotherapy in early HER2-negative breast cancer patients: clinical and translational analysis

Background: Primary breast cancer (BC) has shown a higher immune infiltration than the metastatic disease, justifying the optimal scenario for immunotherapy. Recently, neoadjuvant chemotherapy (NAC) combined with immune checkpoint inhibitors has demonstrated a gain in pathological complete responses (tpCR) in patients with BC. The aim of our study is to evaluate the safety, feasibility, and efficacy of the addition of dendritic cell vaccines (DCV) to NAC in HER2-negative BC patients. Methods: Thirty-nine patients with early BC received DCV together with NAC conforming the vaccinated group (VG) and compared with 44 patients as the control group (CG). All patients received anthracyclines and taxanes-based NAC (ddECx4→Dx4) followed by surgery ± radiotherapy ± hormonotherapy. Results: The tpCR rate was 28.9% in the VG and 9.09% in the CG (p=0.03). Pathological CR in the triple negative (TN) BC were 50.0% versus 30.7% (p=0.25), 16.6% versus 0% in luminal B (p=0.15), and none among luminal A patients in VG versus CG, respectively. Impact of DCV was significantly higher in the programmed cell death ligand 1 (PD-L1) negative population (p<0.001). PD-L1 expression was increased in patients with residual disease in the VG as compared with the CG (p<0.01). No grade ⩾3 vaccine-related adverse events occurred. With a median follow-up of 8years, no changes were seen in event-free survival or overall survival. Phenotypic changes post DCV in peripheral blood were observed in myeloid-derived suppressor cells (MDSC), NK, and T cells. Increase in blood cell proliferation and interferon (IFN)-γ production was detected in 69% and 74% in the VG, respectively. Humoral response was also found. Clonality changes in TCR-β repertoire were detected in 67% of the patients with a drop in diversity index after treatment. Conclusion: The combination of DCV plus NAC is safe and increases tpCR, with a significant benefit among PD-L1-negative tumors. DCV modify tumor milieu and perform cellular and humoral responses in peripheral blood with no impact in outcome. Trial registration: ClinicalTrials.gov number: NCT01431196. EudraCT 2009-017402-36

Final results regarding the addition of dendritic cell vaccines to neoadjuvant chemotherapy in early HER2-negative breast cancer patients: clinical and translational analysis

Background: Primary breast cancer (BC) has shown a higher immune infiltration than the metastatic disease, justifying the optimal scenario for immunotherapy. Recently, neoadjuvant chemotherapy (NAC) combined with immune checkpoint inhibitors has demonstrated a gain in pathological complete responses (tpCR) in patients with BC. The aim of our study is to evaluate the safety, feasibility, and efficacy of the addition of dendritic cell vaccines (DCV) to NAC in HER2-negative BC patients. Methods: Thirty-nine patients with early BC received DCV together with NAC conforming the vaccinated group (VG) and compared with 44 patients as the control group (CG). All patients received anthracyclines and taxanes-based NAC (ddECx4→Dx4) followed by surgery ± radiotherapy ± hormonotherapy. Results: The tpCR rate was 28.9% in the VG and 9.09% in the CG (p = 0.03). Pathological CR in the triple negative (TN) BC were 50.0% versus 30.7% (p = 0.25), 16.6% versus 0% in luminal B (p = 0.15), and none among luminal A patients in VG versus CG, respectively. Impact of DCV was significantly higher in the programmed cell death ligand 1 (PD-L1) negative population (p < 0.001). PD-L1 expression was increased in patients with residual disease in the VG as compared with the CG (p < 0.01). No grade ⩾3 vaccine-related adverse events occurred. With a median follow-up of 8 years, no changes were seen in event-free survival or overall survival. Phenotypic changes post DCV in peripheral blood were observed in myeloid-derived suppressor cells (MDSC), NK, and T cells. Increase in blood cell proliferation and interferon (IFN)-γ production was detected in 69% and 74% in the VG, respectively. Humoral response was also found. Clonality changes in TCR-β repertoire were detected in 67% of the patients with a drop in diversity index after treatment. Conclusion: The combination of DCV plus NAC is safe and increases tpCR, with a significant benefit among PD-L1-negative tumors. DCV modify tumor milieu and perform cellular and humoral responses in peripheral blood with no impact in outcome

Colonic Microbiota Profile Characterization of the Responsiveness to Dietary Fibre Treatment in Hypercholesterolemia

This study aimed to determine how the microbiota profile might be predisposed to a better response in blood lipid profiles due to dietary fibre supplementation. A three-arm intervention study that included three different fibre types (mainly insoluble, soluble, and antioxidant fibre) supplemented (19.2 g/day) during 2 months in individuals with hypercholesterolemia was developed. Changes in faecal microbiota and blood lipid profile after fibre supplementation were determined. In all volunteers, regardless of fibre type, an increase in the abundance of Bifidobacterium was observed, and similarly, an inverse relationship between faecal propionic acid and blood LDL-cholesterol, LDL particle size, and LDL/HDL particle ratio (p-values 0.0067, 0.0002, and 0.0067, respectively) was observed. However, not all volunteers presented an improvement in lipid profile. The non-responders to fibre treatment showed a decrease in microbiota diversity (Shannon and Simpson diversity index p-values of 0.0110 and 0.0255, respectively) after the intervention; where the reduction in short-chain fatty acids (SCFAs) producing bacterial genera such as Clostridium XIVa and Ruminococcus after dietary fibre treatment was the main difference. It was concluded that the non-responsiveness to dietary fibre treatment might be mediated by the lack of ability to maintain a stable SCFA producing bacteria diversity and composition after extra fibre intake.The research leading to these results has received funding from the People Programme (Marie Curie Actions) of the Seventh Framework Programme of the European Union (FP7/2007-2013) under REA grant agreement no. 600388 (TECNIOspring Progamme) and from the Agency for Business Competitiveness of the Government of Catalonia ACCIÓ that support the fellowship given to Ana Belén Granado-Serrano (TECSPR14-0-0023

Dose optimization of TBI-223 for enhanced therapeutic benefit compared to linezolid in antituberculosis regimen.

TBI-223, a novel oxazolidinone for tuberculosis, is designed to provide improved efficacy and safety compared to linezolid in combination with bedaquiline and pretomanid (BPaL). We aim to optimize the dosing of TBI-223 within the BPaL regimen for enhanced therapeutic outcomes. TBI-223 is investigated in preclinical monotherapy, multidrug therapy, and lesion penetration experiments to describe its efficacy and safety versus linezolid. A translational platform incorporating linezolid and BPaL data from preclinical experiments and 4 clinical trials (NCT00396084, NCT02333799, NCT03086486, NCT00816426) is developed, enabling validation of the framework. TBI-223 preclinical and Phase 1 data (NCT03758612) are applied to the translational framework to predict clinical outcomes and optimize TBI-223 dosing in combination with bedaquiline and pretomanid. Results indicate that daily doses of 1200-2400 mg TBI-223 may achieve efficacy comparable to the BPaL regimen, with &gt;90% of patients predicted to reach culture conversion by two months

ATLAS TileCal read-out driver system production and initial performance results

8 pages, 9 figures.-- ISI Article Identifier: 000251744500005The ATLAS Hadronic Tile Calorimeter detector (TileCal) is an iron-scintillating tiles sampling calorimeter designed to operate at the Large Hadron Collider accelerator at CERN. The central element of the back-end system of the TileCal detector is a 9U VME Read-Out Driver (ROD) board. The operation of the TileCal calorimeter requires a total of 32 ROD boards. This paper summarizes the tests performed during the ROD production and the results obtained. Data processing is performed in the ROD by digital signal processors, whose operation is based on the use of online algorithms such as the optimal filtering algorithm for the signal amplitude, pedestal and time reconstruction and the online Muon tagging algorithm which identifies low transverse momentum muons. The initial performance of both algorithms run during commissioning is also presented in this paper.This work was supported by the Spanish Technology and Science Commission under project FPA2003-09220-C02-02.Peer reviewe

Algorithms for the ROD DSP of the ATLAS hadronic Tile Calorimeter

10 pages, 10 figures.-- ISI Article Identifier: 000253651100003.Final full-text version available at: http://ific.uv.es/tical/doc/2007_02_12_JINST_2_T02001.pdfIn this paper we present the performance of two algorithms currently running in the Tile Calorimeter Read-Out Driver boards for the commissioning of ATLAS. The first algorithm presented is the so called Optimal Filtering. It reconstructs the deposited energy in the Tile Calorimeter and the arrival time of the data. The second algorithm is the MTag which tags low transverse momentum muons that may escape the ATLAS muon spectrometer first level trigger.Comparisons between online (inside the Read-Out Drivers) and offline implementations are done with an agreement around 99% for the reconstruction of the amplitude using the Optimal Filtering algorithm and a coincidende of 93% between the offline and online tagged muons for the MTag algorithm. The processing time is measured for both algorithms running together with a resulting time of 59.2 μs which, although above the 10 μs of the first level trigger, it fulfills the requirements of the commissioning trigger (~ 1 Hz). We expect further optimizations of the algorithms which will reduce their processing time below 10 μs.The authors acknowledge the help of Oleg Solovyanov, Giulio Usai, Sasha Solodkov, Tomas Davidek and the whole TileCal community.Peer reviewe

Expert consensus on the use of systemic glucocorticoids for managing eosinophil-related diseases

Eosinophil-related diseases represent a group of pathologic conditions with highly heterogeneous clinical presentation and symptoms ranging from mild to critical. Both systemic and localized forms of disease are typically treated with glucocorticoids. The approval of novel biologic therapies targeting the interleukin-5 pathway can help reduce the use of systemic glucocorticoids (SGC) in eosinophilic diseases and reduce the risk of SGC-related adverse effects (AEs). In this article, a panel of experts from different medical specialties reviewed current evidence on the use of SGC in two systemic eosinophilic diseases: Eosinophilic Granulomatosis with PolyAngiitis (EGPA) and HyperEosinophilic Syndrome (HES); and in two single-organ (respiratory) eosinophilic diseases: Chronic RhinoSinusitis with Nasal Polyps (CRSwNP) and Severe Asthma with Eosinophil Phenotype (SA-EP), and contrasted it with their experience in clinical practice. Using nominal group technique, they reached consensus on key aspects related to the dose and tapering of SGC as well as on the initiation of biologics as SGC-sparing agents. Early treatment with biologics could help prevent AEs associated with medium and long-term use of SGC.Funding: The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The author(s) declare that GSK funded the medical writing support for this manuscript. Acknowledgments: We would like to thank Mónica Hoyos (medical writer) on behalf of Springer Healthcare Communications. This medical writing assistance was funded by GSK and facilitated by Springer Healthcare